200 related articles for article (PubMed ID: 10460158)
1. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
[TBL] [Abstract][Full Text] [Related]
2. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
3. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.
Vaisman A; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2000 Apr; 39(16):4575-80. PubMed ID: 10769112
[TBL] [Abstract][Full Text] [Related]
4. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
McA'Nulty MM; Whitehead JP; Lippard SJ
Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
[TBL] [Abstract][Full Text] [Related]
5. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
Kane SA; Lippard SJ
Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
[TBL] [Abstract][Full Text] [Related]
6. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
[TBL] [Abstract][Full Text] [Related]
7. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
Hoffmann JS; Locker D; Villani G; Leng M
J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
Turchi JJ; Li M; Henkels KM
Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
[TBL] [Abstract][Full Text] [Related]
9. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
Dunham SU; Lippard SJ
Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
[TBL] [Abstract][Full Text] [Related]
10. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
Vaisman A; Chaney SG
J Biol Chem; 2000 Apr; 275(17):13017-25. PubMed ID: 10777605
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
12. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
13. Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts.
Whitehead JP; Lippard SJ
Met Ions Biol Syst; 1996; 32():687-726. PubMed ID: 8640535
[No Abstract] [Full Text] [Related]
14. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
[TBL] [Abstract][Full Text] [Related]
15. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization.
Suo Z; Lippard SJ; Johnson KA
Biochemistry; 1999 Jan; 38(2):715-26. PubMed ID: 9888812
[TBL] [Abstract][Full Text] [Related]
16. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
Comess KM; Burstyn JN; Essigmann JM; Lippard SJ
Biochemistry; 1992 Apr; 31(16):3975-90. PubMed ID: 1314653
[TBL] [Abstract][Full Text] [Related]
17. Impact of the stereochemistry of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxide-deoxyadenosine adducts on resistance to digestion by phosphodiesterases I and II and translesion synthesis with HIV-1 reverse transcriptase.
Chary P; Lloyd RS
Chem Res Toxicol; 1996 Mar; 9(2):409-17. PubMed ID: 8839043
[TBL] [Abstract][Full Text] [Related]
18. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
19. Sequence context modulation of translesion synthesis at a single N-2-acetylaminofluorene adduct located within a mutation hot spot.
Burnouf DY; Miturski R; Fuchs RP
Chem Res Toxicol; 1999 Feb; 12(2):144-50. PubMed ID: 10027791
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
